Financial Ratios Cytokinetics, Incorporated
Stocks
CYTK
US23282W6057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.18 USD | -0.22% |
|
-5.53% | +26.19% |
| 07-14 | Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing | MT |
| 07-07 | RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -16.94 | -21.83 | -33.73 | -30.11 | -27.08 | |||||
Return on Total Capital | -30.4 | -35.02 | -61.23 | -57.92 | -48.85 | |||||
Return On Equity % | -120.54 | -572.15 | 212.96 | 226 | 197.47 | |||||
Return on Common Equity | -120.54 | -572.15 | 212.96 | 226 | 197.47 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -127.09 | -154.59 | -4.28K | -1.74K | -372.55 | |||||
SG&A Margin | 137.45 | 188.16 | 2.31K | 1.17K | 322.89 | |||||
EBITDA Margin % | -261.31 | -336.6 | -6.43K | -2.85K | -683.94 | |||||
EBITA Margin % | -264.54 | -342.75 | -6.59K | -2.9K | -695.44 | |||||
EBIT Margin % | -264.54 | -342.75 | -6.59K | -2.9K | -695.44 | |||||
Income From Continuing Operations Margin % | -305.72 | -411.21 | -6.99K | -3.19K | -891.6 | |||||
Net Income Margin % | -305.72 | -411.21 | -6.99K | -3.19K | -891.6 | |||||
Net Avail. For Common Margin % | -305.72 | -411.21 | -6.99K | -3.19K | -891.6 | |||||
Normalized Net Income Margin | -191.08 | -240.53 | -4.37K | -1.99K | -471.17 | |||||
Levered Free Cash Flow Margin | -255.34 | -134.32 | -3.47K | -1.31K | -431.19 | |||||
Unlevered Free Cash Flow Margin | -229.31 | -100.52 | -2.99K | -1.01K | -357.46 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.1 | 0.1 | 0.01 | 0.02 | 0.06 | |||||
Fixed Assets Turnover | 0.87 | 0.61 | 0.05 | 0.13 | 0.59 | |||||
Receivables Turnover (Average Receivables) | 2.21 | 0.27 | 10.53 | 2.06 | 5.12 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.45 | 9.4 | 6.12 | 6.17 | 4.53 | |||||
Quick Ratio | 7.35 | 9.25 | 6 | 6.08 | 4.45 | |||||
Operating Cash Flow to Current Liabilities | -1.98 | -3.54 | -4.04 | -2.2 | -2.52 | |||||
Days Sales Outstanding (Average Receivables) | 165.17 | 1.37K | 34.66 | 177.64 | 71.34 | |||||
Average Days Payable Outstanding | 33.25 | 35.39 | 26.05 | 22.58 | 18.73 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 110.69 | -696.33 | -195.93 | -681.96 | -218.13 | |||||
Total Debt / Total Capital | 52.54 | 116.77 | 204.25 | 117.18 | 184.65 | |||||
LT Debt/Equity | 104.59 | -683.52 | -188.43 | -650.93 | -204.28 | |||||
Long-Term Debt / Total Capital | 49.64 | 114.62 | 196.43 | 111.85 | 172.92 | |||||
Total Liabilities / Total Assets | 71.01 | 110.63 | 146.87 | 109.66 | 146.3 | |||||
EBIT / Interest Expense | -6.35 | -6.34 | -8.6 | -6.2 | -5.89 | |||||
EBITDA / Interest Expense | -5.72 | -5.8 | -8.4 | -6.09 | -5.8 | |||||
(EBITDA - Capex) / Interest Expense | -7.39 | -6.02 | -8.42 | -6.13 | -6.04 | |||||
Total Debt / EBITDA | -1.61 | -2.53 | -1.56 | -1.75 | -2.39 | |||||
Net Debt / EBITDA | 1.2 | 0.11 | -0.29 | 0.29 | -0.92 | |||||
Total Debt / (EBITDA - Capex) | -1.25 | -2.44 | -1.56 | -1.74 | -2.3 | |||||
Net Debt / (EBITDA - Capex) | 0.93 | 0.1 | -0.29 | 0.29 | -0.89 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 26.15 | 34.3 | -92.04 | 145.34 | 376.56 | |||||
Gross Profit, 1 Yr. Growth % | 117.66 | 63.36 | 120.61 | -0.51 | 2.2 | |||||
EBITDA, 1 Yr. Growth % | 99.8 | 73 | 52.11 | 8.76 | 14.32 | |||||
EBITA, 1 Yr. Growth % | 98.33 | 74.01 | 53.05 | 8.07 | 14.17 | |||||
EBIT, 1 Yr. Growth % | 98.33 | 74.01 | 53.05 | 8.07 | 14.17 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 69.15 | 80.65 | 35.3 | 12.03 | 33.15 | |||||
Net Income, 1 Yr. Growth % | 69.15 | 80.65 | 35.3 | 12.03 | 33.15 | |||||
Normalized Net Income, 1 Yr. Growth % | 69.15 | 69.06 | 44.57 | 12.03 | 12.58 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 41.96 | 54.62 | 25.91 | -3.44 | 24.14 | |||||
Accounts Receivable, 1 Yr. Growth % | 721.08 | -99.74 | 772.79 | 1.2K | 6.69 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 799.87 | 11.46 | -9.47 | -4.58 | 10.07 | |||||
Total Assets, 1 Yr. Growth % | 57.61 | 20.62 | -18.77 | 70.04 | 1.63 | |||||
Tangible Book Value, 1 Yr. Growth % | 115.08 | -144.25 | 258.04 | -64.96 | 387.27 | |||||
Common Equity, 1 Yr. Growth % | 115.08 | -144.25 | 258.04 | -64.96 | 387.27 | |||||
Cash From Operations, 1 Yr. Growth % | -1.69K | 110.15 | 38.33 | -4.45 | 28.83 | |||||
Capital Expenditures, 1 Yr. Growth % | 342.2 | -76.81 | -87.51 | 175.85 | 535.1 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 160.62 | -29.35 | 105.78 | -7.25 | 57.33 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 260.25 | -41.13 | 137.09 | -16.45 | 68.09 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 61.9 | 30.16 | -67.3 | -55.81 | 241.93 | |||||
Gross Profit, 2 Yr. CAGR % | 22.9 | 88.57 | 89.84 | 48.15 | 0.83 | |||||
EBITDA, 2 Yr. CAGR % | 37.34 | 85.92 | 62.22 | 28.62 | 11.5 | |||||
EBITA, 2 Yr. CAGR % | 37.28 | 85.77 | 63.2 | 28.61 | 11.08 | |||||
EBIT, 2 Yr. CAGR % | 37.28 | 85.77 | 63.2 | 28.61 | 11.08 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 33.02 | 74.8 | 56.34 | 23.11 | 22.13 | |||||
Net Income, 2 Yr. CAGR % | 33.02 | 74.8 | 56.34 | 23.11 | 22.13 | |||||
Normalized Net Income, 2 Yr. CAGR % | 33.02 | 69.11 | 56.34 | 27.26 | 12.3 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 15.11 | 48.15 | 39.53 | 10.26 | 9.49 | |||||
Accounts Receivable, 2 Yr. CAGR % | 231.74 | -85.43 | -84.97 | 964.26 | 272.1 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 230.4 | 216.7 | 0.45 | -7.06 | 2.49 | |||||
Total Assets, 2 Yr. CAGR % | 70.38 | 37.88 | -1.02 | 17.53 | 31.46 | |||||
Tangible Book Value, 2 Yr. CAGR % | 372.2 | -2.45 | 25.86 | 12.01 | 30.67 | |||||
Common Equity, 2 Yr. CAGR % | 372.2 | -2.45 | 25.86 | 12.01 | 30.67 | |||||
Cash From Operations, 2 Yr. CAGR % | 25.21 | 478.72 | 70.5 | 14.97 | 10.95 | |||||
Capital Expenditures, 2 Yr. CAGR % | 331.98 | 1.27 | -82.98 | -41.3 | 318.56 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 63.42 | 35.69 | 20.56 | 37.89 | 20.75 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 79.3 | 45.63 | 18.12 | 40.43 | 18.44 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 30.76 | 52.12 | -48.72 | -35.99 | -2.36 | |||||
Gross Profit, 3 Yr. CAGR % | 15.81 | 35.13 | 98.7 | 53.06 | 30.9 | |||||
EBITDA, 3 Yr. CAGR % | 28.04 | 48.32 | 73.89 | 41.98 | 23.66 | |||||
EBITA, 3 Yr. CAGR % | 27.96 | 48.57 | 74.15 | 42.25 | 23.61 | |||||
EBIT, 3 Yr. CAGR % | 27.96 | 48.57 | 74.15 | 42.25 | 23.61 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 26.53 | 47.3 | 60.5 | 39.9 | 26.37 | |||||
Net Income, 3 Yr. CAGR % | 26.53 | 47.3 | 60.5 | 39.9 | 26.37 | |||||
Normalized Net Income, 3 Yr. CAGR % | 26.53 | 44.09 | 60.5 | 39.9 | 22.17 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 12.76 | 27.01 | 40.33 | 23.42 | 14.71 | |||||
Accounts Receivable, 3 Yr. CAGR % | 103.07 | -69.46 | -42.98 | -33.58 | 394.4 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 247 | 130 | 108.62 | -1.25 | -1.67 | |||||
Total Assets, 3 Yr. CAGR % | 58.53 | 51.85 | 15.59 | 18.55 | 11.97 | |||||
Tangible Book Value, 3 Yr. CAGR % | 111.07 | 114.47 | 50.48 | -17.81 | 82.85 | |||||
Common Equity, 3 Yr. CAGR % | 111.07 | 114.47 | 50.48 | -17.81 | 82.85 | |||||
Cash From Operations, 3 Yr. CAGR % | 12.08 | 48.8 | 259.16 | 40.57 | 19.41 | |||||
Capital Expenditures, 3 Yr. CAGR % | 280.24 | 62.97 | -49.59 | -56.93 | 29.83 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 33.65 | 23.57 | 55.88 | 10.33 | 44.05 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 37.7 | 23.7 | 71.29 | 5.09 | 49.05 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -7.92 | 47.9 | -24.89 | -7.22 | 9.54 | |||||
Gross Profit, 5 Yr. CAGR % | 16.33 | 13.71 | 41.12 | 40.2 | 51.48 | |||||
EBITDA, 5 Yr. CAGR % | 65.26 | 23.35 | 40.75 | 40.1 | 45.57 | |||||
EBITA, 5 Yr. CAGR % | 67.37 | 23.38 | 41.04 | 40.24 | 45.48 | |||||
EBIT, 5 Yr. CAGR % | 67.37 | 23.38 | 41.04 | 40.24 | 45.48 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 67.25 | 24.93 | 37.7 | 37.1 | 43.88 | |||||
Net Income, 5 Yr. CAGR % | 67.25 | 24.93 | 37.7 | 37.1 | 43.88 | |||||
Normalized Net Income, 5 Yr. CAGR % | 78.34 | 23.28 | 37.7 | 37.1 | 39.14 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 48.33 | 10.85 | 22.79 | 20.02 | 27.07 | |||||
Accounts Receivable, 5 Yr. CAGR % | 372.99 | -33.28 | -28.33 | 26.39 | 20.75 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 109.39 | 114.81 | 111.34 | 60.08 | 57 | |||||
Total Assets, 5 Yr. CAGR % | 37.67 | 28.05 | 31.31 | 37.06 | 21.69 | |||||
Tangible Book Value, 5 Yr. CAGR % | 20.91 | -0.36 | 71.64 | 65.4 | 42.22 | |||||
Common Equity, 5 Yr. CAGR % | 20.91 | -0.36 | 71.64 | 65.4 | 42.22 | |||||
Cash From Operations, 5 Yr. CAGR % | 30.97 | 24.1 | 32.56 | 34.21 | 124.5 | |||||
Capital Expenditures, 5 Yr. CAGR % | 98.25 | 31.55 | 9.76 | 8.32 | 17.55 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 72.24 | 11.19 | 28.25 | 29.1 | 40.64 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 64.16 | 8.19 | 29.5 | 30.13 | 47.66 |
- Stock Market
- Stocks
- CYTK Stock
- Financials Cytokinetics, Incorporated
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















